Sung H. Lee's Insider Trades & SAST Disclosures
Sung H. Lee's most recent trade in Cytokinetics Inc was a trade of 41,326 Non-Qualified Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Sung H. Lee.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cytokinetics Inc | Sung H. Lee | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 41,326 | 41,326 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Sung H. Lee | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 32,687 | 74,442 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Sung H. Lee | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 9,016 | 9,016 | - | - | Incentive Stock Option (Right to Buy) | |
| Cytokinetics Inc | Sung H. Lee | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2024 | 4,304 | 41,755 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Sung H. Lee | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Dec 2024 | 4,303 | 38,987 (0%) | 0% | 0 | Common Stock | |
| Cytokinetics Inc | Sung H. Lee | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 51.51 per share. | 03 Dec 2024 | 1,536 | 37,451 (0%) | 0% | 51.5 | 79,119 | Common Stock |
| Cytokinetics Inc | Sung H. Lee | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 53,417 | 53,417 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Cytokinetics Inc | Sung H. Lee | EVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 34,684 | 34,684 (0%) | 0% | 0 | Common Stock | |
| Vir Biotechnology Inc | Sung H. Lee | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 9.89 per share. | 27 Mar 2024 | 6,008 | 100,492 (0%) | 0% | 9.9 | 59,404 | Common Stock |
| Vir Biotechnology Inc | H. Sung Lee | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Lee H. Sung | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 40,000 | 106,500 (0%) | 0% | 0 | Common Stock | |
| Vir Biotechnology Inc | Sung H. Lee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2023 | 133,000 | 133,000 | - | - | Stock Option (Right to Buy) | |
| Vir Biotechnology Inc | Sung H. Lee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2023 | 66,500 | 66,500 (0%) | 0% | 0 | Common Stock | |
| Sangamo Therapeutics Inc | Sung H. Lee | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.77 per share. | 25 Nov 2020 | 5,042 | 88,708 (0%) | 0% | 9.8 | 49,260 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges